Skip to main content
. 2024 Apr 11;30(4):990–1000. doi: 10.1038/s41591-024-02848-4

Fig. 4. FPM-guided therapies provide significant clinical benefit in patients with refractory or relapsed pediatric cancer.

Fig. 4

a, Swimmer plot illustrating patient best objective response and PFS to treatments assigned following FPMTB review, grouped by FPM-guided and TPC-treated patients. Agents beside each patient represent treatments given during the study. P value determined by two-sided Barnard’s test. b, Comparison of PFS in the TPC-treated and FPM-guided cohorts. P value determined by logrank test analysis of Kaplan–Meier survival data. c, Comparison between the PFS of the trial regimen and the PFS of the patient’s previous regimen in the FPM-guided cohort. P value is from two-sided Cox proportional hazards test of paired survival data. d, Comparison of PFS from the previous regimen (orange in bar graph) and trial regimens for both FPM-guided (blue in bar graph) and TPC (black in bar graph) cohorts, with indications for patients with a PFS ratio of ≥1.3× (light green boxes above indicated patients) and <1.3× (light red boxes above indicated patients). P value determined by two-sided Barnard’s test analysis of occurrences of PFS ratio of ≥1.3×. e, Difference in PFS of the previous regimens and trial regimens for FPM-guided (left) and TPC-treated (right) cohorts. Asterisk, five patients who received TPC and had the same previous and trial regimen PFS. P values for each cohort determined by two-sided paired Wilcoxon test. P value between cohort determined by two-sided Mann–Whitney U-test of PFS ratio values. Light green dots indicate patients with a PFS ratio of ≥1.3× (top), light red dots indicate patients with a PFS ratio of <1.3×, and orange dots indicate the PFS of the previous regimen for both cohorts.